03c0

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Kerr-Conte et al.

Examiner:

Unassigned

Serial No .:

09/960,632

Group Art Unit:

Unassigned

Confirmation No.:

4273

Docket:

855-21

Filed:

September 21, 2001

Dated:

April 8, 2002

For:

PROCESS FOR OBTAINING

MAMMALIAN INSULIN SECRETING CELLS IN VITRO AND THEIR USES

US Patent and Trademark Office Box Sequence PO Box 2327 Arlington, VA 22202 I hereby certify this correspondence is being deposited with the United States Postal Service as first class mail, postpaid in an envelope, addressed to:

U.S. Patent and Trademark Office, Box Sequence,

PO Box 2327, Arlington, VA 22202

20231 on April 8, 2002

Signature: MUSC POOLS

COMMUNICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATION CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Sir:

In response to a Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosure mailed February 8, 2002, Applicants enclose herewith the following:

- 1. A substitute diskette containing the Sequence Listing in computer-readable form;
- 2. A substitute paper copy of the Sequence Listing; and
- 3. A copy of the Notice.

Application No.: 09/960,632 Filing Date: September 21, 2001

Docket: 855-21

Page 2

Applicants submit that the Sequence Listing conforms with the Notification to Comply.

Under 37 C.F.R. 1.821(f), the Applicants' attorney hereby states that the contents of the computer readable form and the paper copy are the same. Under 37 C.F.R. §1.821(g), the Applicants' attorney also states that the inclusion of this Sequence Listing does not include any new matter.

Accordingly, it is respectfully requested that the Sequence Listing be entered into the application.

If the Examiner has any questions relating to this Amendment or to this application in general, it is respectfully requested that the Examiner contact the Applicants' undersigned attorney at the telephone number provided below.

Respectfully submitted,

Lauren T. Emr


Registration No. 46,139

HOFMANN & BARON, LLP 6900 Jericho Turnpike Syosset, New York 11791 (516) 822-3550 LTE/nr



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov



NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE